Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Longevity Biotech


Longevity Biotech (LBT) is developing a new class of innovative therapeutics based on the patented Hybridtide® platform technology. Hybridtides are based on a unique synthetic peptide scaffold that provides critical enhancements and is differentiated compared to other peptide scaffolds. The most important feature of this breakthrough technology is the prospect of oral delivery of Hybridtide-based peptide therapeutics. Our goal is to remove the frequent injections required for traditional biologic therapeutics and switch them into pill form.


Importantly, Hybridtides are highly stabilized (structurally and digestively) linear peptides that allow for the pursuit of complex molecular targets and protein-protein interfaces. We expect these drug candidates to become breakthrough treatments in their respective therapeutic areas as each program focuses on an entirely new way to treat disease. LBT’s candidates display unique attributes that are expected to provide either first-in-class or best-in-class product profiles in their respective indication. The Hybridtide technology has been developed by Prof. Sam Gellman at the University of Wisconsin – Madison and has been widely published in leading journals.


Longevity Biotech has multiple therapeutic programs based on the Hybridtide® core technology, including: LBT-3627, a novel neuroprotective agent for Neuroinflammatory diseases (e.g. Parkinson’s disease and Multiple Sclerosis); LBT-6030, a Gastric Inhibitory Polypeptide dual agonist that targets the validated glucagon receptor for Diabetes; along with other preclinical programs targeting severe asthma (5A apoA-I mimetic); HIV (a GP41 fusion inhibitor) in addition to unnamed oncology and cholesterol programs. Meanwhile, the Hybridtide scaffold is available for specific partnership opportunities, please contact the Business Development team (BD@LongevityBiotech.com) for more information.


Breakout Labs

Michael J. Fox Foundation

National Institute of Health

National MS Society

National Science Foundation (NSF)



Therapeutics – Platform Technologies

Management Team

Scott Shandler, Ph.D., MBA, CEO

Sam Gellman, Ph.D., CSO

Company HQ

Philadelphia, PA, USA



Longevity Biotech - NetScientific